Please assess the completion status of the following clinical trial:

Trial Title: Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
CASES Specific Aim #1 Inclusion Criteria~* A history of chronic (greater than 3 month) ulcerative colitis or Crohn's disease diagnosed and documented by the standard clinical, radiographic, endoscopic and histopathologic criteria.~* Ages 18-64~* Currently taking anti-TNF therapy (infliximab, golilumab, adalimumab, or certolizumab) for at least 3 months~* Exclusion Criteria~* Received season's influenza vaccine~* Allergy to eggs or influenza vaccine~* Currently use of systemic steroids in the past 3 months~Specific Aim #2 Inclusion criteria~* A history of chronic (greater than 3 month) ulcerative colitis or Crohn's disease diagnosed and documented by the standard clinical, radiographic, endoscopic and histopathologic criteria.~* Ages 18-64~* Currently on vedolizumab therapy~Exclusion Criteria~* Received season's influenza vaccine~* Allergy to eggs or influenza vaccine~* Currently use of systemic steroids in the past 3 months~Control group Inclusion criteria~* Age 18-64~* Willing to participate in study~Control group Exclusion criteria~* Currently on immunosuppressive therapy~* Has a chronic health condition that may have an impact on vaccine antibody concentrations as deemed by the investigators, including chronic liver disease, celiac disease, history of solid organ or bone marrow transplantation.~* Older than age 65 years~* Unconfirmed Measles, Mumps, and Rubella (MMR) vaccination status~* Patients in whom venipuncture are not feasible due to poor tolerability or lack of easy access.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: OTHER): A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.
- Vedolizumab Group + standard dose influenza vaccine (SDIV) (Type: OTHER): A group of 20 patients who are currently on vedolizumab. All individuals in this group will receive SDIV
- High dose influenza vaccine (HDIV) (Type: OTHER): This arm will be a double blind randomized controlled trial of High dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.~40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.
- Standard dose influenza vaccine (SDIV) (Type: OTHER): This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.~40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete